RxDoctor Payments DataLook up a doctor →

Stacy Younger, MD

Neurology · Overland Park, KSNPI 1043212210

Payments from drug & device makers

$22,236in general payments, 2019–2025

Across 1,384 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$2K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$1K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)133$2,176
Biogen95$1,613
Novartis88$1,377
Teva Pharmaceuticals USA, Inc.139$1,279
UCB, Inc.70$1,123
EMD Serono, Inc.74$1,040
Genentech USA, Inc.59$1,008
Jazz Pharmaceuticals Inc.36$874
Sanofi44$865
Lilly USA, LLC47$813
Bristol Myers Squibb40$736
AstraZeneca30$689
Amgen44$683
Pfizer64$677
Argenx US, Inc.21$447
Neurocrine Biosciences, Inc.23$430
Catalyst Pharmaceuticals, Inc.23$422
Banner Life Sciences, LLC18$401
Lundbeck LLC22$388
Amneal Pharmaceuticals LLC23$358
CSL Behring16$325
SK Life Science, Inc.18$293
Grifols USA, LLC12$278
Johnson & Johnson(2 entities)10$267
Acadia Pharmaceuticals Inc15$261
Vanda Pharmaceuticals Inc.9$225
Kyowa Kirin, Inc.13$220
Supernus Pharmaceuticals, Inc.12$193
Takeda Pharmaceuticals U.S.A., Inc.8$187
Upsher-smith Laboratories LLC8$184
Acorda Therapeutics, Inc9$165
Biohaven Pharmaceutical Holding Company Ltd.24$152
Biohaven Pharmaceuticals, Inc.30$149
Impel Pharmaceuticals Inc.8$136
Alnylam Pharmaceuticals Inc.7$128
Greenwich Biosciences, Inc.5$124
Arbor Pharmaceuticals, Inc.8$120
Zyla Life Sciences, Inc.7$102
Corium, LLC6$102
Ultragenyx Pharmaceutical Inc.5$97
Axsome Therapeutics, Inc.4$88
E.r. Squibb & Sons, L.L.C.5$74
Abbott3$72
TG Therapeutics, Inc.3$71
Eisai Inc.5$71
Azurity Pharmaceuticals, Inc.4$70
Neurelis, Inc.3$67
Scilex Pharmaceuticals Inc.3$59
Xeris Pharmaceuticals, Inc.3$56
Adamas Pharmaceuticals, Inc.3$54
Livanova USA, Inc.2$49
Aquestive Therapeutics, Inc.3$45
Octapharma USA, Inc.2$33
Assertio Therapeutics, Inc.2$31
Promius Pharma LLC2$29
Mallinckrodt Enterprises LLC2$29
Harmony Biosciences LLC1$27
Hospira, Inc.1$26
Bio Products Laboratory USA, Inc.1$23
Cycle Pharmaceuticals Inc1$22

How this compares

$22,236 in reported general payments places this provider in the 80th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas →

Medicare billing

Part B allowed, 2024
$88,451
Medicare patients
407
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Overland Park

See the full list for Kansas →

Where these figures come from

Is this you, or does something look wrong? →